Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

SSL sells Regent to Apax in £173m deal

Damian Reece
Monday 24 May 2004 00:00 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Durex condoms maker, SSL International, has agreed to sell Regent Infection Control to Apax Partners in a deal worth £173m.

Durex condoms maker, SSL International, has agreed to sell Regent Infection Control to Apax Partners in a deal worth £173m.

The management buyout of the SSL business, which comprises the Biogel surgical gloves operation and the Hibi antiseptics business, was finalised late on Friday night. It will allow SSL to lower its near £300m debt pile.

This is the second deal with Apax in just over a month. In mid-April SSL sold its bandages business, Medlock Medical, to Apax for £55m. More details of the latest transaction with Apax are expected to be revealed on Thursday when SSL announces its full-year results.

The deal with Apax is the culmination of a radical restructuring programme that has so far raised £250m. However, the weakening dollar means the final sum raised from asset sales will fall £40m short of SSL's original target of £300m.

News of the sale of the surgical gloves and antiseptics division will hearten the City. Shareholders have seen SSL suffer torrid times recently, including a scandal over false invoices that resulted in a Serious Fraud Office investigation with five former directors charged in November.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in